Evidence map›Paper›PMID 35696523›Full record

ReviewAnnual review of analytical chemistry (Palo Alto, Calif.)2022

Saliva Diagnostics.

Taichiro Nonaka, David T W Wong

Open access · bronzeAbstract readReview
In one paragraph

Review in Annual review of analytical chemistry (Palo Alto, Calif.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 7 pooled it
14.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 7 syntheses or guidelines pooled it, 126 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Taichiro NonakaDepartment of Cellular Biology and Anatomy, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA; email: taichiro.nonaka@lsuhs.edu.
David T W WongDivision of Oral Biology and Medicine, School of Dentistry, University of California, Los Angeles, California; email: dtww@ucla.edu.
Louisiana State University Health Sciences Center Shreveport · USUniversity of California, Los Angeles · US

Funding

EFIRM Liquid Biopsy Research Laboratory: Early Lung Cancer AssessmentU01CA233370 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ABERLE, DENISE R., HSU, WILLIAM · 2018 to 2025
$8.0M
Oral Fluid NanoSensor Test (OFNASET)U01DE017790 · NIDCR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WONG, DAVID T · 2006 to 2010
$7.3M
AFS/SERS Saliva-based SARS-CoV-2 Earliest Infection and Antibodies DetectionU18TR003778 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HUANG, TONY JUN, KIM, YONG · 2021 to 2022
$1.8M
Acoustofluidic Separation (AFS), Purification and Raman Spectral Fingerprinting of Single EVs: From Cell of Origin to Target Cell and BiofluidsUH3TR002978 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GALL, KENNETH A, HUANG, TONY JUN · 2021 to 2022
$1.8M
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC PatientsUH3CA206126 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHIA, DAVID S., SOO HOO, GUY · 2019 to 2021
$1.2M
Acoustofluidic Separation (AFS), Purification and Raman Spectral Fingerprinting of Single EVs: From Cell of Origin to Target Cell and BiofluidsUG3TR002978 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AN, JI YEONG, GALL, KENNETH A · 2019 to 2020
$823k
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC PatientsUH2CA206126 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHIA, DAVID S., DAS, KINGSHUK · 2017 to 2018
$368k
Immunomodulatory effects of cytomegalovirus-induced salivary soluble form of NHC class IR03DE027759 · NIDCR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NONAKA, TAICHIRO · 2018 to 2019
$311k
Defining a novel function for salivary exosomes in modulating host immunity against cancerR03DE029272 · NIDCR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NONAKA, TAICHIRO · 2020 to 2021
$305k
NCATS NIH HHS U18 TR003778NCATS NIH HHS UG3 TR002978NCATS NIH HHS UH3 TR002978NCI NIH HHS U01 CA233370NCI NIH HHS UH2 CA206126NCI NIH HHS UH3 CA206126NIDCR NIH HHS R03 DE027759NIDCR NIH HHS R03 DE029272NIDCR NIH HHS U01 DE017790
6 · The paper itself

Abstract

Cancer remains one of the leading causes of death, and early detection of this disease is crucial for increasing survival rates. Although cancer can be diagnosed following tissue biopsy, the biopsy procedure is invasive; liquid biopsy provides an alternative that is more comfortable for the patient. While blood, urine, and cerebral spinal fluid can all be used as a source of liquid biopsy, saliva is an ideal source of body fluid that is readily available and easily collected in the most noninvasive manner. Characterization of salivary constituents in the disease setting provides critical data for understanding pathophysiology and the evaluation of diagnostic potential. The aim of saliva diagnostics is therefore to develop a rapid and noninvasive detection of oral and systemic diseases that could be used together with compact analysis systems in the clinic to facilitate point-of-care diagnostics.

Indexed as

NeoplasmsSalivaBiomarkers, TumorEarly Detection of CancerHumansLiquid BiopsyBiomarkers, Tumorcirculating biomarkerssaliva exosomicssaliva liquid biopsysalivaomicssalivary exosomes

Identifiers

PMID35696523
PMCPMC9348814
OpenAlexW4282597606

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.